Jennifer L. DiGiacinto, Pharm.D.

Research Projects

1. William Rodriguez, M.D., Ph.D.; Arzu Selen, Ph.D.; Debbie Avant, R.Ph.; Chandra Chaurasia, Ph.D.; Terrie Crescenzi, R.Ph.; Gerlie Gieser, Ph.D.; Jennifer DiGiacinto, Pharm.D.; Shiew-Mei Huang, Ph.D.; Peter Lee, Ph.D.; Lisa Mathis, M.D.; Dianne Murphy, M.D.; Shirley Murphy, M.D.; Rosemary Roberts, M.D.; Hari Cheryl Sachs, M.D.; Sandra Suarez, Ph.D.; Veneeta Tandon, Ph.D.; and Ramana S. Uppoor, Ph.D. Improving Pediatric Dosing Through Pediatric Initiatives - What We Have Learned. Manuscript submitted to JAMA; October 2006.
2. DiGiacinto JL, Bergman KL, Hoie EB, Olsen KM, University of Nebraska Medical Center, College of Pharmacy. The Stability of Liquid Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes, Research Completed, Manuscript Submitted for Publication, Poster Presentation at ASHP Midyear Meeting, December 1998, Las Vegas, NV.
3. DiGiacinto JL, Hoie EB, University of Nebraska Medical Center, College of Pharmacy, The Stability of Intravenous Formulation of Indomethacin, Manuscript Published.
4. Calderon CL, DiGiacinto JL, Blough L, McLaughlin R, Scheibel LW, Graumlich JF University of Illinois College of Medicine at Peoria, Collagen for Treatment of Pressure Ulcers, Research Currently in Progress.
5. DiGiacinto JL, Bysani GK, Scheibel LW, Graumlich JF, University of Illinois College of Medicine at Peoria, Pharmacokinetic and Pharmacodynamic Study Using Lansoprazole Simplified Oral Suspension in Critically Ill Pediatric Patients, IRB approved, Study Completed, Manuscript in Progress.
6. DiGiacinto JL, Steidley KR, Daley J, Graumlich JF, UIC College of Medicine at Peoria, Determining if Carbamazepine is a Substrate for P-Glycoprotein Using LLC-PKI and CAC02 Cells, Research Completed.

Manuscripts and Publications

1. Terkeltaub RA, Furst D, DiGiacinto JL, Kook KA, Davis MW. Pharmacokinetic Studies of Differential Inhibitors of Cytochrome P450 3A4 and P-Glycoprotein Provide Novel, Specific Dosing Recommendations for Colchicine to Avoid Drug-Drug Interactions. Arthritis Rheum., August 2011, Volume 63, p 2226-2237.
2. Anthony R. Godfrey, Jennifer DiGiacinto, Matthew W. Davis. Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover Clinical Trials. Clinical Therapeutics, June 2011, Volume 33(6), p 766-775.
3. DiGiacinto JL, Chan-Tack K, Robertson SR, Reynolds KS, Struble KS, US FDA, Are Literature References Sufficient for Dose Recommendations? An FDA Case Study of Efavirenz and Rifampin. Manuscript Submitted to J. Clin Pharm. April 2008.
4. J Marcinak, S Vora, S Weber, S Garcia-Houchins, S Gerber, R Panares, B Suter, K Siegfried, C Conover, J Nawrocki, K Hunt, R Teclaw, C Graves, W Staggs, D Allen, K Buffin, P Pontones, V Fulginiti, L Collins, D Scott, P Patel, K Chan-Tack, J DiGiacinto, I Damon, M Reynolds, R Regnery, E. Belay, K. Karem, V. Olson, Y. Li, S. Smith, Z. Braden, C. Hughes, A Fleischauer, P Diaz, L Rotz, N Pesik, J Barson, W Bower, R Miramontes, E Lederman, and J Openshaw. Transmission of Vaccinia virus Associated with Smallpox Vaccination in a Household Setting - Illinois and Indiana, 2007. MMWR Volume 56, No. 19, May 18th, 2007.
5. William Rodriguez, M.D., Ph.D.; Arzu Selen, Ph.D.; Debbie Avant, R.Ph.; Chandra Chaurasia, Ph.D.; Terrie Crescenzi, R.Ph.; Gerlie Gieser, Ph.D.; Jennifer Di Giacinto, Pharm.D.; Shiew-Mei Huang, Ph.D.; Peter Lee, Ph.D.; Lisa Mathis, M.D.; Dianne Murphy, M.D.; Shirley Murphy, M.D.; Rosemary Roberts, M.D.; Hari Cheryl Sachs, M.D.; Sandra Suarez, Ph.D.; Veneeta Tandon, Ph.D.; and Ramana S. Uppoor, Ph.D. Improving Pediatric Dosing Through Pediatric Initiatives - What We Have Learned. Submitted to Lancet April 2007.
6. DiGiacinto JL, Graumlich JF, Bysani GK, Torres A, Shusliunov S, Kastrissios H, Wohrley J, Scheibel LW. Pharmacokinetic and Pharmacodynamic Study Using Lansoprazole Simplified Oral Suspension in Critically Ill Pediatric Patients, Manuscript Submitted to Journal of Clinical Pharmacology and Therapeutics.
7. DiGiacinto JL, Bergman KL, Hoie EB, Olsen KM. The Stability of Liquid Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes, Ann. Pharmacother. 2000 May; 34(5): 600-5.
8. DiGiacinto JL, Hoie EB. The Stability of Intravenous Formulation of Indomethacin, Journal of Pediatric Pharmacology and Therapeutics 2001; 6:311-14.

Presentations

1. Davis MW, Wason S, DiGiacinto J. Multiple-dose colchicine administration, as prescribed for prophylactic treatment of gout, has no effect on single-dose theophylline plasma concentrations in healthy volunteers. Presented at American College of Clinical Pharmacy (ACCP) annual meeting. October 17-20, 2010; Austin, TX. Abstract 22834.
2. Davis MW, Wason S, DiGiacinto J. Dosing modifications are required for concomitant administration of colchicine and cyclosporine. Presented at American Society of Nephrology (ASN) annual meeting. November 16-21, 2010; Denver, CO. Abstract 4482.
3. Davis MW, Wason S, DiGiacinto J. Coadministration of colchicine with the potent P-gp and CYP3A4 inhibitor, ketoconazole, substantially increases colchicine exposure. American Society of Clinical Pharmacology & Therapeutics (ASCPT) annual meeting. Accepted for poster presentation March 3, 2011; Dallas, TX. Poster PI-64.
4. Davis MW, Wason S, DiGiacinto J. The Effect of Multiple Dose Atorvastatin on the Single-Dose Pharmacokinetics of Colchicine Administered to Healthy Adult Subjects as a Single 0.6-mg Dose Under Fasted Conditions . American College of Cardiology 60th Annual Scientific Session and Expo. April 3-5, New Orleans Louisiana. Accepted for poster presentation
5. DiGiacinto J, Wason S. Effects of macrolide antibiotics azithromycin and clarithromycin on the pharmacokinetics of colchicine. American Society of Clinical Pharmacology & Therapeutics (ASCPT) annual meeting. Accepted for poster presentation March 3, 2011; Dallas, TX. Poster PI-78.
6. Terkeltaub R, Furst D, DiGiacinto J, Kook K, Davis MW. A one sequence, two-period pharmacokinetic drug-drug interaction study with colchicine reveals profound effects of clarithromycin (a macrolide antibiotic) on the pharmacokinetic profile of colchicine in healthy adults. Presented at American College of Rheumatology (ACR) annual congress. October 28, 2008. San Francisco, CA. Presentation 1946.
7. Terkeltaub R, Furst DE, Kook K, DiGiacinto J, Davis MW. New dosing guidelines for colchicine to avoid toxicity when used with Ca2+ channel blockers: The potent P-Gp/CYP3A4 inhibitor verapamil increases maximal concentration of single-dose colchicine by 30% and exposure by ~100% in healthy subjects. Presented at American College of Rheumatology (ACR) annual congress. October 19, 2009. Philadelphia, PA. Presentation 1107.
8. Wason S, DiGiacinto J, Davis MW. Consumption of grapefruit or Seville orange juice does not affect the pharmacokinetics of colchicine. American Society of Clinical Pharmacology & Therapeutics (ASCPT) annual meeting. Accepted for poster presentation March 3, 2011; Dallas, TX. Poster PI-77.